Related Experiment Video
Updated: Aug 9, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Cancer vaccines
1Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Abstract:
1993 represents the 100th anniversary of William Coley's first report of tumor regressions induced by immune system activation in response to bacterial toxins. While many subsequent cancer vaccine trials have yielded tantalizing results, active immunotherapy has not yet become an established modality of cancer therapy. Newer molecular vaccine approaches based on rational immunological principles have resulted in improved systemic antitumor effects in animal models. Ultimately the genetic definition of tumor-specific antigens will allow the development of targeted antigen-specific vaccines for cancer therapy.
Insights
Cancer immunotherapy, pioneered by William Coley, shows promise but isn't standard therapy. Newer molecular vaccines and defining tumor antigens may lead to effective, targeted cancer vaccines.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- William Coley's 1893 report marked the 100th anniversary of early cancer immunotherapy using bacterial toxins.
- Despite early promise, active immunotherapy has not become a standard cancer treatment modality.
- Cancer vaccines have historically yielded mixed results in clinical trials.
Purpose of the Study:
- To review the historical context and current state of cancer immunotherapy.
- To highlight advancements in molecular vaccine approaches.
- To discuss the future potential of antigen-specific cancer vaccines.
Main Methods:
- Historical review of cancer immunotherapy research.
- Analysis of recent advancements in molecular vaccine design.
- Discussion of the role of tumor-specific antigens in vaccine development.
Main Results:
- Early immunotherapy showed tumor regressions but lacked consistent efficacy.
- Modern molecular vaccine strategies demonstrate improved systemic antitumor effects in preclinical models.
- Identification of tumor-specific antigens is crucial for targeted vaccine development.
Conclusions:
- Active immunotherapy remains a developing field in cancer treatment.
- Molecular vaccine approaches offer a rational path toward more effective cancer therapies.
- Targeted, antigen-specific vaccines hold significant future potential for cancer treatment.
Related Concept Videos
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

